GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Net Change in Cash

ValiRx (LSE:VAL) Net Change in Cash : £-0.08 Mil (TTM As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

ValiRx's Net Change in Cash for the six months ended in Jun. 2024 was £0.64 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.08 Mil.

ValiRx Net Change in Cash Historical Data

The historical data trend for ValiRx's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Net Change in Cash Chart

ValiRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 1.85 -1.25 0.54 -0.96

ValiRx Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 1.04 -0.25 -0.72 0.64

ValiRx Net Change in Cash Calculation

ValiRx's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.772+-0.306+1.116+0
=-0.96

ValiRx's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.89+-0.052+1.577+0
=0.64

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ValiRx Net Change in Cash Related Terms

Thank you for viewing the detailed overview of ValiRx's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Net Change in Cash
Comparable Companies
LSE:PYC LSE:NFX LSE:ONC LSE:ROQ LSE:CRTX LSE:BSFA LSE:GENF LSE:TCF LSE:APTA LSE:CIZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
EAJF:Germany
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
Website
https://www.valirx.com
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.